Advertisement

Topics

Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

09:54 EST 9 Nov 2017 | BioPortfolio Reports

Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Pipeline Review, H2 2017


Summary


Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Pipeline Review, H2 2017, outlays comprehensive information on the Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the betacell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulinsensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes Juvenile Diabetes and Obesity.


Furthermore, this report also reviews key players involved in Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2

The report reviews Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics and enlists all their major and minor projects

The report assesses Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Glucokinase Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...